"Labrys takes a lower risk approach to drug development with a promising clinical stage asset which addresses a significant medical need – chronic migraine. We have the opportunity to take LBR-101 deep into development and build the greatest value—a vision that is shared and supported by IW."
LeadershipSteve James, President and CEO
Labrys Biologics is a private, venture-financed development stage biotechnology company focused on treatments for chronic migraine. Labrys' lead candidate, LBR-101 (formerly known as RN-307), is an anti-CGRP monoclonal antibody which has completed Phase 1.